tavokinogene telseplasmid
Gene therapyexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2012 (NCT01579318)
Timeline
Indications
Mechanism of action
- Interleukin-12 subunit betaSupplementation
IL12B supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298206 ↗
Also known as
- il-12 plasmid
- tavokinogene telseplasmid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04627675 | Phase 1 | Dec 31, 2020 | OncoSec Medical Incorporated, Providence Health & Services |
| NCT04526730 | Phase 2 | Aug 20, 2020 | OncoSec Medical Incorporated, University of South Florida |
| NCT03567720 | Phase 2 | Aug 31, 2018 | OncoSec Medical Incorporated |
| NCT03132675 | Phase 2 | Oct 3, 2017 | Merck, OncoSec Medical Incorporated |
| NCT01579318 | Phase 2 | Jul 1, 2012 | OncoSec Medical Incorporated |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| OncoSec Medical Incorporated | For profit | 5 | 3 | 2 | 2012 |
| Merck | For profit | 1 | 0 | 1 | 2017 |
| Providence Health & Services | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1